Phase 2 Brain Cancer Trial, Recruiting NCT07100600 Sponsor: Henan Cancer Hospital Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07100600
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who have been diagnosed through laboratory testing with HER2-positive advanced breast cancer
  • People who have at least one measurable tumour in the brain (according to specific measurement guidelines called RANO-BM criteria) that has not yet been treated locally (such as with surgery or radiation)
  • People who have not previously had radiation to the brain, and for whom immediate local brain treatment is either not medically required or who have chosen not to pursue local treatment
  • People whose life expectancy is at least 6 months
  • People whose major organs (such as the heart, liver, and kidneys) are functioning adequately

Who may not be able to join:

  • People whose cancer has spread to the lining surrounding the brain and spinal cord (called leptomeningeal metastasis)
  • People who have brain-related complications that require urgent surgery
  • People who have previously been treated with the drug trastuzumab deruxtecan (DS-8201a), or any similar type of drug from the same drug class (antibody drug conjugates that include a topoisomerase 1 inhibitor)
  • People with heart disease that is not well managed or that is causing noticeable symptoms
  • People with a history of serious lung disease
  • People who have been diagnosed with another cancer in the past five years, apart from certain treated skin cancers or cervical carcinoma in situ that has been cured
  • People who are currently pregnant or breastfeeding
  • People whom the research team considers unsuitable for the study for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Henan Cancer Hospital
Registry
ClinicalTrials.gov
Start date
30 August 2025
Est. completion
30 July 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov